References
- Klimo P., Connors J. M. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann. Intern. Med 1985; 102: 596–602
- Skarin A. T., Canellos G. P., Rosenthal D. S. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin. Oncol. 1983; 1: 91–98
- Canellos G. P., Skarin A. T., Klatt M. M. The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Semin. Hematol 1987; 24: 2–7
- The COP-BLAM programs. Evolving chemotherapy concepts in large cell lymphoma. Semin. Hematol 1988; 25(suppl 2)23–33
- Longo D. L., De vita V. T., Jr, Duffey P. L. Superiority of Pro Mace-Cyta BOM over Pro Mace-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J. Clin. Oncol 1991; 9: 25–38
- Coiffier B., Gisselbrecht C., Herbrecht R. LNH 84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J. Clin. Oncol 1989; 7: 1018–1026
- Armitage J. O., Fyfe M. A., Lewis J. Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J. Clin. Oncol 1984; 5: 898–902
- Coltman A. C., Jr, Dahlberg S., Jones E. S. CHOP is curative in thirty per cent of patients with large cell lymphoma: a twelve year southwest oncology group follow-up. Update on treatment for diffuse large cell lymphoma, A. T. Skarin. Park row, New York 1986; 71–77
- Connors J. M., Klimo P. MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 Update and additional observations. Semin. Hematol 1988; 25: 41–46
- The non Hodgkin's lymphoma classification project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphoma. Summary and description of a working formulation for clinical usage. Cancer, 49: 2112–2135
- Carbone P. P., Kaplan H. S., Musshoff K. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971; 31: 1860–1861
- Kaplan E. L., Meier P. Non parametric estimation from incomplete observations. J. Am. Stat. Assoc 1958; 53: 157–18
- Vitolo U., Bertini M., Tarella C. MACOP-B treatment for advanced stage diffuse large cell lymphoma: a multicenter Italian study. Eur. J. Cancer Clin. Oncol 1989; 25: 1441–1449
- Oster W., Forsthuber T., Hennekeuser J. H. MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma. Blut 1990; 60: 23–27
- Froimtchuck M., Olivatto C. O., Gil R. A. MACOP-B effective treatment for diffuse unfavourable non Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol, (abstr.) 1988; 7: C-936
- Lowenthal D. A., White A., Koziner B. MACOP-B for advanced diffuse intermediate and high grade non Hodgkin's lymphoma (NHL). Preliminary results for the Memorial Hospital experience. Proc. Am. Clin. Oncol (abstr.) 1987; 6: 201
- Weick J. K., Dahlberg S., Fischer R. I. Combination chemotherapy of intermediate-grade and high-grade non Hodgkin's lymphoma with MACOP-B: A southwest oncology group study. J. Clin. Oncol 1991; 9: 748–753
- Cooper I. A., Ding J. C., Matthews J. P. A randomized comparison of MACOP-B and CHOP in intermediate grade non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol, (abstr.) 1991; 10: 942
- Vose J. M., Armitage J. O., Wesenburger D. D. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J. Clin. Oncol 1988; 6: 1838–1844
- Jagannath S., Velasquez W. S., Tucker S. L. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J. Clin. Oncol 1986; 4: 859–865
- Shipp M. A., Harrington D. P., Klatt M. M. Identification of major prognostic subgroups of patients with large cell lymphoma treated with m-BACOD or M-BACOD. Ann. Intern. Med 1986; 104: 757–765
- Cowan R. A., Jones M., Harris M. Prognostic factors in high and intermediate grade non Hodgkin's lymphoma. Br. J. Cancer 1989; 59: 276–282
- Danieu L., Wong G., Koziner B. Predictive model for prognosis in advanced diffuse histiocytic lymphoma. Cancer Res. 1986; 46: 5372–5379
- Ferraris A. M., Giuntini P., Gaetani G. F. Serum Lactic dehydrogenase as a prognostic tool for non Hodgkin's lymphomas. Blood 1979; 54: 928–932
- Coiffier B., Gisselbrecht C., Vose J. M. Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J. Clin. Oncol. 1991; 9: 211–219
- Hoskins P. J., Ng V., Spinelli J. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J. Clin. Oncol 1991; 9: 220–226
- Slymen D. J., Miller T. P., Lippman S. M. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J Clin. Oncol. 1990; 8: 986–993
- Gianni A. M., Bregni M., Siena S. Prospective randomized comparison of MACOP-B vs. rhGM-CSF supported high-dose sequential myeloablative chemo-radio-therapy in diffuse large cell lymphomas. Proc. Am. Soc. Clin. Oncol. (abstr.) 1991; 10: 951